The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients

  • Kang, Eunjung (Department of Nephrology, Ajou University School of Medicine) ;
  • Kim, Seihran (Department of Nephrology, Ajou University School of Medicine) ;
  • Lee, Hwa Jung (Department of Nephrology, Ajou University School of Medicine) ;
  • Park, Inhwee (Department of Nephrology, Ajou University School of Medicine) ;
  • Kim, Heungsoo (Department of Nephrology, Ajou University School of Medicine) ;
  • Shin, Gyu-Tae (Department of Nephrology, Ajou University School of Medicine)
  • Received : 2015.07.20
  • Accepted : 2015.08.28
  • Published : 2016.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: It has been shown that circulating tumor necrosis factor ${\alpha}$ ($TNF-{\alpha}$) is elevated in end stage renal disease patients; however, the relationship between $TNF-{\alpha}$ and the development of infection in these patients is unknown. In this study, we investigated the association of plasma $TNF-{\alpha}$ and interleukin 6 (IL-6) with infection in peritoneal dialysis (PD) patients. We also evaluated the association of their plasma levels with the production by peripheral blood mononuclear cells (PBMC), and with various clinical parameters. Methods: We enrolled 32 patients on maintenance PD and 10 healthy controls. Plasma and PBMC were isolated from blood. PBMC were stimulated with lipopolysaccharide in vitro. Results: Mean follow-up duration was 775 days. Six patients developed organ infections (five pneumonia and one liver abscess), and six patients developed PD peritonitis and eight developed exit site infection. Plasma $TNF-{\alpha}$ and IL-6 levels were significantly elevated in organ infections but not in peritonitis or in exit site infection. Plasma $TNF-{\alpha}$ was the only significant risk factor for organ infections and pneumonia in multivariate regression analysis. Patients with high plasma $TNF-{\alpha}$ levels showed a significantly greater cumulative hazard rate for organ infections compared to those with low $TNF-{\alpha}$ levels. Plasma $TNF-{\alpha}$ levels correlated with $TNF-{\alpha}$ production by PBMC and showed an inverse association with Kt/V. Conclusions: This is the first study showing that plasma $TNF-{\alpha}$ is a significant risk factor for infection in PD patients.

Keywords

References

  1. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998;13:1476-1483. https://doi.org/10.1093/ndt/13.6.1476
  2. Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010;77:550-556. https://doi.org/10.1038/ki.2009.503
  3. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16 Suppl 1:S83-S88. https://doi.org/10.1681/ASN.2004110972
  4. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-1688. https://doi.org/10.1093/ndt/17.9.1684
  5. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114. https://doi.org/10.1053/ajkd.1998.v32.pm9669431
  6. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-1218. https://doi.org/10.1016/S0272-6386(03)00353-6
  7. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993;150:2007-2017.
  8. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995;47:559-565. https://doi.org/10.1038/ki.1995.70
  9. Girndt M, Sester U, Kaul H, Kohler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998;9:1689-1696.
  10. Canpolat N, Caliskan S, Sever L, et al. Malnutrition and its association with inflammation and vascular disease in children on maintenance dialysis. Pediatr Nephrol 2013;28:2149-2156. https://doi.org/10.1007/s00467-013-2527-3
  11. Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-${\alpha}$ are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-2667. https://doi.org/10.1093/ndt/gfq760
  12. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004;15:1877-1882. https://doi.org/10.1097/01.ASN.0000131523.17045.56
  13. Goldstein SL, Leung JC, Silverstein DM. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 2006;1:979-986. https://doi.org/10.2215/CJN.02291205
  14. Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pena-Quintero P, Gomez-Navarro B, Cueto-Manzano AM. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double- blind, controlled clinical trial. Nephrol Dial Transplant 2012;27:2023-2028. https://doi.org/10.1093/ndt/gfr579
  15. Echtenacher B, Mannel DN. Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis. J Endotoxin Res 2002;8:365-369. https://doi.org/10.1179/096805102125000696
  16. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988;56:2563-2569.
  17. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-953. https://doi.org/10.1016/S0140-6736(05)60606-X
  18. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002;65:33-38.
  19. Cendoroglo M, Sundaram S, Jaber BL, Pereira BJ. Effect of glucose concentration, osmolality, and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro. Am J Kidney Dis 1998;31:273-282. https://doi.org/10.1053/ajkd.1998.v31.pm9469498
  20. MacKenzie RK, Holmes CJ, Moseley A, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. J Am Soc Nephrol 1998;9:1499-1506.
  21. Plum J, Schoenicke G, Grabensee B. Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity. Am J Kidney Dis 1997;30:413-422. https://doi.org/10.1016/S0272-6386(97)90287-0
  22. Jorres A, Gahl GM, Ludat K, Frei U, Passlick-Deetjen J. In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1997;12:543-549. https://doi.org/10.1093/ndt/12.3.543
  23. Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995;47:282-293. https://doi.org/10.1038/ki.1995.36
  24. Rogachev B, Hausmann MJ, Yulzari R, et al. Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFalpha production by peritoneal macrophages. Perit Dial Int 1997;17:546-553.
  25. Douvdevani A, Rapoport J, Konforti A, Zlotnik M, Chaimovitz C. The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes. Perit Dial Int 1993;13:112-117.
  26. Dwyer JT, Larive B, Leung J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 2005;68:1766-1776. https://doi.org/10.1111/j.1523-1755.2005.00593.x
  27. Beabaa N, Ozdemir S, Saatci U, et al. Nutritional assessment of children on haemodialysis: value of IGF-I, TNF-alpha and IL-1beta. Nephrol Dial Transplant 1998;13:1484-1488. https://doi.org/10.1093/ndt/13.6.1484
  28. Paniagua R, Ventura Mde J, Rodriguez E, et al. Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int 2004;24:156-162.
  29. Pawelec GP, Rehbein A, Schaudt K, Busch FW. IL-4-responsive human helper T cell clones are resistant to growth inhibition by tumor necrosis factor-alpha. J Immunol 1989;143:902-906.

Cited by

  1. The Behavior of the Type of Peritoneal Transport in the Inflammatory and Oxidative Status in Adults Under Peritoneal Dialysis vol.6, pp.None, 2019, https://doi.org/10.3389/fmed.2019.00210
  2. Assessment of hemodialysis clinical practices using polyaryl ether sulfone-polyvinylpyrrolidone (PAES: PVP) clinical membrane: Modeling of in vitro fibrinogen adsorption, in situ synchrotron-based ima vol.259, pp.None, 2016, https://doi.org/10.1016/j.seppur.2020.118136